Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes and liver danger: new study follows 317 patients to uncover hidden risks

NCT ID NCT07312136

Knowledge-focused Sponsor: Linkoeping University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 317 adults with type 2 diabetes who were first examined between 2019 and 2023. Researchers will repeat advanced liver scans, blood tests, and body composition measurements to see how liver fat and scarring change over time. The goal is to find out who is most at risk for serious liver disease and what factors—like physical activity, sleep apnea, or genetics—drive progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict who will develop serious liver problems and guide earlier, more personalized care.
What could go wrong
This is an observational follow-up study, not a treatment trial. It cannot prove that any intervention works, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 317 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who where previously included, and fulfilled participation, in the EPSONIP trial (NCT03864510) between 2019 and 2023 are re-invited to fulfill the same evaluation with additional tests.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Previously included and fulfilled evaluation in EPSONIP trial (NCT03864510) * Age \>/= 18 years * Informed consent Exclusion Criteria: * Contraindication to magnetic resonance * Other primary liver disease than MASLD diagnosed after inclusion EPSONIP trial (NCT03864510) * Liver transplantation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced fibrosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome cirrhosis of liver Fibrosis hypertensive disorder metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder obstructive sleep apnea syndrome Overweight Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Advanced fibrosis Cirrhosis Hypertension Masld (metabolic dysfunction-associated steatotic liver disease) Metabolic syndrome Obesity & overweight Osas (obstructive sleep apneas syndrome) Sarcopenia Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Gastroenterology and Hepatology, Linköping University Hospital

    Linköping, Östergötland County, 58185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.